Dose Adaptation of Capecitabine Using Mobile Phone Toxicity Monitoring
NCT01053104 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 26
Last updated 2012-07-25
Summary
To develop a system to manage side effects and adjust chemotherapy dose such that a patient can receive their personal maximum tolerated dose.
Conditions
Sponsors & Collaborators
-
oxBRC
collaborator UNKNOWN -
Vodafone UK Foundation
collaborator UNKNOWN -
Centre for Statistics in Medicine
collaborator OTHER -
Oncology Clinical Trials Office (OCTO, Oxford)
collaborator UNKNOWN -
University of Oxford
lead OTHER
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2009-11-30
- Primary Completion
- 2010-12-31
- Completion
- 2011-04-30
Countries
- United Kingdom
Study Locations
More Related Trials
-
Pharmacokinetic Study on the Addition of Aprepitant to Cisplatin - Etoposide Treatment in Lung Cancer Patients
NCT00588835 ·Status: TERMINATED ·Phase: PHASE4
-
Association of Genetic Polymorphisms With Capecitabine-based Chemotherapy Toxicities in Chinese Solid Tumor Patients
NCT03258099 ·Status: UNKNOWN
-
Pharmacist-led Intervention on Adherence in Patients Undergoing Treatment With an Oral Oncology Medication
NCT03104114 ·Status: COMPLETED ·Phase: NA
-
Evaluation of ReX-C® System for Medication Adherence in Oncology Patients Taking Oral Oncolytics
NCT04091711 ·Status: SUSPENDED ·Phase: NA
-
The Validation of a Novel Adherence Method for Oral Oncolytics
NCT03561272 ·Status: COMPLETED ·Phase: NA
-
Paclitaxel Therapeutic Drug Monitoring in Cancer Patients
NCT03987555 ·Status: SUSPENDED
-
A Study To Determine If Two Different Versions Of Topotecan Have The Same Potency In Patients With Advanced Solid Tumors
NCT00259935 ·Status: COMPLETED ·Phase: PHASE1
-
Collaborative Network to Take Responsibility for Oral Anticancer Therapy 2
NCT04142463 ·Status: UNKNOWN ·Phase: NA
-
Wearable Sensors and Molecular Omics to Detect and Mitigate Cell Therapy Adverse Events
NCT05123001 ·Status: COMPLETED
-
Collaborative Network to Take Responsibility for Oral Anticancer Therapy
NCT02861209 ·Status: UNKNOWN ·Phase: NA
-
Docetaxel in Treating Older Patients With Metastatic Breast, Lung, or Prostate Cancer
NCT00059943 ·Status: COMPLETED ·Phase: PHASE2
-
Smartphone App for Cancer Medication Adherence
NCT05225090 ·Status: COMPLETED ·Phase: NA
-
Dose-finding Study of BP-C1 in Patients With Stage IV Breast Cancer
NCT04298333 ·Status: COMPLETED ·Phase: PHASE1
-
Pharmacogenomic and Pharmacokinetic Safety and Cost-saving Analysis in Patients Treated With Fluoropyrimidines
NCT00838370 ·Status: COMPLETED ·Phase: PHASE1
-
Preparatory Work to Assess Adherence to Oral Chemotherapy
NCT02895542 ·Status: COMPLETED
-
Pharmacogenomic Testing to Personalize Supportive Oncology
NCT04500301 ·Status: COMPLETED ·Phase: NA
-
Safety, Feasibility and Cost-effectiveness of Genotype-directed Individualized Dosing of Fluoropyrimidines
NCT02324452 ·Status: COMPLETED ·Phase: NA
-
Effectiveness of Pharmacist Intervention on Capecitabine Relative Dose Intensity, Adherence, Knowledge & Safety Among Cancer Patients in Malaysia
NCT04175899 ·Status: UNKNOWN ·Phase: NA
-
The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study
NCT06377852 ·Status: RECRUITING ·Phase: PHASE3
-
Nivestim™ in Treatment of Malignant Diseases
NCT01627990 ·Status: COMPLETED
-
Software Monitoring of Treatment Related Toxicities in Advanced Renal Cell Carcinoma
NCT03229083 ·Status: COMPLETED ·Phase: NA
-
Pharmacogenomic Study in Patients of Lung, Colorectal and Head/Neck Cancers Receiving Chemotherapy
NCT00442520 ·Status: COMPLETED
-
Pharmacokinetic Boosting of Osimertinib
NCT03858491 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
OPTI - DOSE: Optimal Dosing of Oral Anticancer Drugs in Older Adults
NCT05949424 ·Status: NOT_YET_RECRUITING ·Phase: PHASE4
-
Open-Label Study to Determine the Maximum Tolerated Oral Dose of the Kinase Inhibitor CEP-11981 in Patients With Advanced Cancer
NCT00875264 ·Status: COMPLETED ·Phase: PHASE1